Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trials
Matthew S. Davids(Dana-Farber Cancer Institute), John C. Byrd(University of Cincinnati), Jeff P. Sharman(Willamette Valley Cancer Institute and Research Center), Jennifer A. Woyach(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Ugochinyere Emeribe(AstraZeneca (United States)), Toby A. Eyre(Oxford University Hospitals NHS Trust), Mina Shahkarami(AstraZeneca (Netherlands)), Paulo Miranda(AstraZeneca (United States)), Paolo Ghia(Vita-Salute San Raffaele University), Wojciech Jurczak(Jagiellonian University), Anna Butturini(AstraZeneca (United States)), Tanya Siddiqi(City Of Hope National Medical Center)
Cited by 18
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|9.9k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k